- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bayer Mirena approved in Europe for extended duration of use in contraception
Berlin: Bayer has announced that it has positively concluded the European Workshare Procedure extending the duration of use for up to eight years in contraception of its levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena for countries in Europe.
This regulatory approval in Europe is based on the results of the Mirena Extension Trial evaluating the efficacy and safety of Mirena which demonstrated that contraceptive efficacy remains high with greater than 99% during years six to eight of use. Following the completion of the European Workshare procedure the first national approvals in the EU are expected in Q4 2022.
"With the positive clearance of the approval process in Europe we are pleased to be able to offer soon the extended label also to women in Europe, and with this enriching the range of contraceptive methods as individual contraceptive needs are changing throughout the reproductive life", said Dr. Michael Devoy, Chief Medical Officer at Bayer AG.
The European approval also includes symptom-driven extended use for the indication idiopathic menorrhagia (heavy menstrual bleeding) for up to eight years or until symptoms return. The IUS should be removed or replaced after eight years at the latest.
Read also: Trial evaluates contraceptive efficacy of Mirena Intrauterine System through 8 years
In August 2022, Bayer received U.S. approval for the extended duration of use for up to eight years in the contraception indication for its levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena.
A LNG-IUS is one of the most effective birth control methods as it does not require user compliance such as daily dosing or monthly re-fills. It can be removed by the doctor at any time and offers a rapid return to a woman's natural level of fertility after removal. A LNG-IUS should only be inserted after a comprehensive discussion and evaluation of all contraceptive options and the individual woman's needs.
Read also: Bayer concludes sale of Environmental Science Professional business to Cinven
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751